Point: use of pharmacogenetics in guiding treatment with warfarin.
Wadelius
Mia
M
Department of Medical Sciences, Clinical Pharmacology, Uppsala University Hospital, Uppsala, Sweden. mia.wadelius@medsci.uu.se
D000483:Alleles; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D004194:Disease; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics / Q000378:metabolism; D010597:Pharmacogenetics; D014859:Warfarin / Q000737:chemistry / Q000627:therapeutic use*
C400322:cytochrome P-450 CYP2C subfamily; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases